Currently, there are many therapeutic strategies for DN, but the effectiveness of treatment varies, among which SIRT3, glycolysis inhibitors, DPP-4 inhibitors (e.g., linagliptin), ROCK inhibitors, mineralocorticoid receptor antagonists, and peptide AcSDKP are more widely used in clinical and scientific research to prevent kidney injury (Castoldi et al., 2013; Zhao et al., 2020). The gene discussed is DPP4; the disease is liver dysplastic nodule.